Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to Nicole Concin, MD, PhD, as she highlights important clinical trial data for ovarian and endometrial cancers presented at the ESGO 2021 annual meeting.
Nicole Concin, MD, PhD
Released: November 23, 2021

In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:

  • Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
  • Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
  • Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer

Information on this Educational Activity

Faculty

Nicole Concin, MD, PhD

Professor
Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany

Nicole Concin, MD, PhD, has disclosed that she has received consulting fees from Akesobio, AstraZeneca, Ensai, eTheRNA immunotherapies NV, GlaxoSmithKline, Mersana, and Seattle Genetics and other financial or material support from Amgen, Genmab, MSD, and Roche.

Program Medium

This program has been made available online.

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Experts review key data for ovarian, endometrial, and cervical cancers from the 2022 SGO, ASCO, ESMO, IGCS, and ESGO meetings, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2023 Expired: January 22, 2024

Expert commentary on HRD testing, PARP inhibitor, and quality-of-life studies in rare ovarian cancer from the 2022 ESGO Congress, from Clinical Care Options (CCO)

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: December 2, 2022

Podcast episode with expert thoughts on studies of interest presented at the 2022 ESGO annual meeting in Berlin, Germany, from Clinical Care Options (CCO)

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: November 30, 2022

Podcast with transmasculine cancer survivor Yee Won Chong and gynecologic oncologist Dr Norma Steiner discussing their insights on cancer care for transgender patients, from Clinical Care Options (CCO)

person default Yee Won Chong person default Norma Steiner, MD Released: November 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings